**Myanmar Support for Measles-Rubella Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country**: Myanmar

2. **Grant number**: 17-MMR-09a-X

3. **Date of Decision Letter**: 22 December 2016

4. **Date of the Partnership Framework Agreement**: 4 April 2014

5. **Programme title**: New vaccine support (NVS), Measles-Rubella MSD

6. **Vaccine type**: Measles-Rubella

7. **Requested product presentation and formulation of vaccine**: Measles Rubella, 10 dose(s) per vial, LYOPHILISED

8. **Programme duration**: 2012 - 2017

9. **Programme Budget (indicative)**: (subject to the terms of the Partnership Framework Agreement)

| Programme Budget (US$) | 2012-2016 | 2017 | Total
|-------------------------|-----------|------|------|
|                         | US$2,730,556<sup>3</sup> | US$357,000 | US$3,087,556<sup>2</sup>

10. **Vaccine introduction grant (in US$)**: Not applicable.

11. **Indicative Annual Amounts** (subject to the terms of the Partnership Framework Agreement)<sup>4</sup>

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2012-2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Measles-Rubella vaccines doses</td>
<td></td>
<td>1,209,800</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$2,730,556&lt;sup&gt;5&lt;/sup&gt;</td>
<td>US$357,000</td>
</tr>
</tbody>
</table>

12. **Procurement agency**: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. **Self-procurement**: Not applicable

14. **Co-financing obligations**: Not applicable

15. **Operational support for campaigns**: Not applicable

---

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.
16. **Additional reporting requirements:** Not applicable

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications:** The country shall address any recommendations, prioritised needs or strategic actions as described in the High Level Review Panel Report (October 2016)*

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

18. **Other conditions:**

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

<table>
<thead>
<tr>
<th>Number of doses of vaccines for Measles Second Dose approved by Gavi</th>
<th>1,209,800</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount for vaccines approved by Gavi in US$ (excluding freight and insurance)</td>
<td>338,744</td>
</tr>
<tr>
<td>Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support</td>
<td>555,318</td>
</tr>
<tr>
<td>Number of doses of Measles-Rubella vaccine to be funded by country</td>
<td>654,482</td>
</tr>
<tr>
<td>Amount for Measles-Rubella vaccines to be funded by Country in US$ (excluding freight and insurance)</td>
<td>399,234</td>
</tr>
</tbody>
</table>

In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

Signed by,

On behalf of Gavi

Hind Khalib-Othman
Managing Director, Country Programmes
22 December 2016

Barry Greene
Managing Director
Finance & Operations
The Gavi Alliance